Compared with PD-1 inhibitors, PD-L1 inhibitors can bind PD-L1 on the surface of both tumor cells and antigen-presenting cells, which is conducive to the full activation of T cells and restoration of T cell-mediated antitumor immunity, with stronger overall immune efficacy and without affecting the physiological function of PD-L2. The gene discussed is CD274; the disease is neoplasm.